

Tobin Strom, MD

Department of Radiation Oncology
Texas Oncology
5400 Kell West Blvd
Wichita Falls, TX 76310
940-691-8271

Overview:

After graduating with honors from Brown University with a degree in Computational Biology, Dr. Strom spent four years in an academic research lab studying and developing pharmaceutical metabolites. He then attended the University of Colorado School of Medicine, where he was immediately drawn to the field of radiation oncology, which combined his background in computer science with his desire to work at the forefront of cancer research and build a patient-centered practice. He completed his internship at Boston University's Roger Williams Medical Center and his residency at the H. Lee Moffitt Cancer Center, which treats the third highest volume of cancer patients in the nation. As one of the most prolific researchers in the program's history, he was selected "Chief Resident" and offered a position as an attending physician.

Dr. Strom and his wife are both from rural Colorado, however, and they wanted to move back west to raise their daughters. He accepted a position as an attending physician at UT Southwestern, where he focused his research on head & neck cancers and skin cancers. His initial plan was to spend 3-5 years in academic medicine before opening a practice in a more rural community, but when the opportunity in Wichita Falls opened up, it was a perfect fit. Dr. Strom was extremely impressed with the medical oncology team and the clinical staff at Texas Oncology, who are completely devoted to patient care. Since joining the practice, Dr. Strom has started a brachytherapy program and a stereotactic radiosurgery program. He is referred patients from all over northern Texas, and has physicians in Dallas referring to his Wichita Falls practice.

Dr. Strom has published 49 peer-reviewed, academic publications, including 21 first-name publications. His work has been cited by academic researchers over 700 times to-date, and his publications continue to be cited at a rate of approximately 10 times per month. Although he has left UT Southwestern, his academic work has not ended. He continues to edit publications with former colleagues and to review peer-reviewed manuscripts for the Red Journal, the top radiation oncology journal in America. Additionally, Dr. Strom spends hours each week reading the latest radiation oncology research studies, which benefits his patients, and has allowed him to serve as a mock-examiner for the Radiation Oncology Board Exam.

Like his own father – a family doctor who would fly into remote areas of Wyoming to treat patients in farming and ranching communities – Dr. Strom has always believed that the best-trained academic physicians should practice in America's heartland, where the need is often greatest. "No patient should ever have to drive hours each day or live away from their family to receive state-of-the-art, cutting-edge cancer treatment."

When not treating patients or editing medical publications, Dr. Strom spends his time with his wife and two daughters. He and his family enjoy camping, riding bikes, exploring Texas, and cheering at the girls' soccer matches and swim meets.

Current Position:

Aug 2017 – present Board Certified Radiation Oncologist, Texas Oncology, Wichita Falls, TX

Committees: ASTRO Head & Neck Abstract Review Committee
Radiation Quality Control, Texas Oncology
Rad Onc Clinical Excellence & Pathways, US Oncology

Memberships: 2016 – present; Texas Radiological Society
2016 – present; Texas Medical Association
2016 – present; Wichita County Medical Society
2012 – present; American Society for Radiation Oncology
2012 – present; American Brachytherapy Society

Academics: 2018 KU Rad Onc Mock-Oral Board Examiner
2017 ASTRO Head & Neck Scientific Session Moderator
2015 – present; Int'l Journal of Rad Oncology Biology Physics (primary academic Rad Onc journal) Study/Manuscript Reviewer

Academic Positions:

Aug 2016 – Aug 2017 Assistant Professor, Radiation Oncology, UT Southwestern, Dallas, TX

Committees: Head & Neck Tumor Board
Melanoma Tumor Board
Base of Skull Tumor Board
UTSW Promotional and Branding Committee
UTSW Resident Selection Committee

Clinical Trials: Authored Phase II trial on Stereotactic Radiosurgery (SRS)
Enrolled patients on multiple active clinical trials

Specialized Training:

Intensity Modulated Radiation Therapy (IMRT) with Image Guided Radiation Therapy (IGRT)
Volumetric Modulated Arc Therapy (VMAT)
Cyberknife-based Stereotactic Body Radiotherapy (SBRT)
Linac-based Stereotactic Radiosurgery (SRS)
High-dose-rate (HDR) & Low-dose-rate (LDR) Brachytherapy for skin, cervical, endometrial, prostate
MIM, Pinnacle and Eclipse treatment planning

Education / Medical Training:

2015 – 2016 Chief Resident, Radiation Oncology, H. Lee Moffitt Cancer Center, Tampa, FL
2012 – 2016 Resident, Radiation Oncology, H. Lee Moffitt Cancer Center, Tampa, FL
2011 – 2012 Intern, Boston University - Roger Williams Medical Center, Providence, RI
2007 – 2011 M.D., University of Colorado Health Sciences Center, Denver, CO
1999 – 2003 B.S. with honors in Computational Biology, Brown University, Providence, RI

Awards/Recognition:

2015 – 2016 K05 Research Scientist Award, Moffitt Cancer Center
2015 – 2016 Chief Resident, Moffitt Cancer Center
2014 Editorial Recognition, Desmoplastic Melanoma manuscript in *Cancer*, May 2014
2014 Moffitt Scientific Symposium Clinical Research Award
2008 NIH Summer Research Grant, University of Colorado Dept. of Pathology
2005 Subspecialty Award, Renal and Electrolyte Abstract Submission, Western Student Medical Research Forum, Carmel, CA
2003 Honors Award for Molecular Biology Thesis, Brown University
2003 – 2007 Sigma Xi Research Honor Society, Brown University Chapter
1999 Fort Collins High School Valedictorian

Academic Research:

- 2016 – 2017 Clinical Research Focused on Head and Neck and Cutaneous Malignancies
University of Texas Southwestern, Dallas, TX
- 2012 – 2016 Resident Research Focused in Head and Neck, Central Nervous System,
Gastrointestinal, Genitourinary and Cutaneous Malignancies
H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
- 2010 – 2011 Medical Student Research, Department of Radiation Oncology
University of Colorado Health Sciences Center (UCHSC), Denver, CO
- 2008 Medical Student Research
Dept. of Pathology, Neurosurgery & Pediatric Neurology, UCHSC, Denver, CO
- 2003 – 2007 Senior Professional Research Assistant (2005-2007)
Professional Research Assistant (2003-2005)
Dept. of Anesthesiology Research and Development, UCHSC, Denver, CO
- 2002 – 2003 Senior Undergraduate Research Project, Department of Molecular
Pharmacology, Physiology and Biotechnology, Brown University, Providence, RI

Leadership/Service:

- 2016 – 2017 Resident Selection Committee, UT Southwestern Radiation Oncology, Dallas, TX
- 2013 – 2016 Resident Representative, Moffitt Cancer Center Board of Ethics, Tampa, FL
- 2007 – 2009 Co-Leader, Nutrition & Preventative Health Interest Group, UCHSC, Denver, CO
- 2008 Developed Self Assessment Module for pathologists based on authored
manuscript (see below), UCHSC, Denver, CO
- 2009 – present Alumni Interviewer, Brown University Area Selection Committee

Peer Reviewed Publications:

1. Oliver DE, Sondak VK, **Strom T**, Zager JS, Naghavi AO, Sarnaik A, Messina JL, Caudell JJ, Trotti AM, Torres-Roca JF, Khushalani NI, Harrison LB. Interferon is associated with improved survival for node-positive cutaneous melanoma: a single-institution experience. *Melanoma Manag.* 2018 Apr 9;5(1):MMT02. [PMID: 30190928]
2. Naghavi AO, Echevarria MI, **Strom T**, Abuodeh YA, Venkat PS, Ahmed KA, Demetriou S, Frakes JM, Kim Y, Kish JA, Russell JS, Otto KJ, Chung CH, Harrison LB, Trotti A, Caudell JJ. Patient choice for high-volume center radiation impacts head and neck cancer outcome. *Cancer Med.* 2018 Sep 2. [PMID: 3017552]
3. Jin WH, Hoffe SE, Shridhar R, **Strom T**, Venkat P, Springett GM, Hodul PJ, Pimiento JM, Meredith KL, Malafa MP, Frakes JM. Adjuvant radiation provides survival benefit for resected pancreatic adenocarcinomas of the tail. *J Gastrointest Oncol.* 2018 Jun;9(3):487-494. [PMID: 29998014]
4. Chiu T, Tan J, Brenner M, Gu X, Yang M, Westover K, **Strom T**, Sher D, Jiang S, Zhao B. Three-dimensional printer-aided casting of soft, custom silicone boluses (SCSBs) for head and neck radiation therapy. *Pract Radiat Oncol.* 2018 May - Jun;8(3):e167-e174. [PMID: 29452869]
5. **Strom T**, Harrison LB, Giuliano AR, Schell MJ, Eschrich SA, Berglund A, Fulp W, Thapa R, Coppola D, Kim S, Frakes J, Foekens J, Mulé JJ, Torres-Roca JF. Tumour radiosensitivity is associated with immune activation in solid tumours. *Eur J Cancer.* 2017 Oct;84:304-314. [PMID: 28863385]

6. **Strom T**, Torres-Roca JF, Parekh A, Naghavi AO, Caudell JJ, Oliver DE, Messina JL, Khushalani NI, Zager JS, Sarnaik A, Mulé JJ, Trotti AM, Eschrich SA, Sondak VK, Harrison LB. Regional Radiation Therapy Impacts Outcome for Node Positive Cutaneous Melanoma. *J Natl Compr Canc Netw*. 2017 Apr;15(4):473-482. [PMID: 28404758]
7. Naghavi AO, Gonzalez RJ, Scott JG, Kim Y, Abuodeh YA, **Strom T**, Echevarria M, Mullinax JE, Ahmed KA, Harrison LB, Fernandez DC. Staged reconstruction brachytherapy has lower overall cost in recurrent soft-tissue sarcoma. *J Contemp Brachytherapy*. 2017 Feb;9(1):20-29. [PMID: 28344600]
8. Scott JG, Berglund A, Schell MJ, Mihaylov I, Fulp WJ, Yue B, Welsh E, Caudell JJ, Ahmed K, **Strom T**, Mellon E, Venkat P, Johnstone P, Foekens J, Lee J, Moros E, Dalton WS, Eschrich SA, McLeod H, Harrison LB, Torres-Roca JF. A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study. *Lancet Oncol*. 2017 Feb;18(2):202-211. [PMID: 27993569]
9. Mellon EA, Jin WH, Frakes JM, Centeno BA, **Strom T**, Springett GM, Malafa MP, Shridhar R, Hodul PJ, Hoffe SE. Predictors and survival for pathologic tumor response grade in borderline resectable and locally advanced pancreatic cancer treated with induction chemotherapy and neoadjuvant stereotactic body radiotherapy. *Acta Oncol*. 2017 Mar;56(3):391-397. [PMID: 27885876]
10. **Strom T**, Naghavi AO, Trotti AM, Russell J, Kish JA, McCaffrey J, Otto KJ, Harrison LB, Caudell JJ. Increased acute mortality with chemoradiotherapy for locally advanced head and neck cancer in patients ≥ 70 years. *J Ger Oncol*. 2017 Jan;8(1):50-55. [PMID: 27720129]
11. Naghavi AO, Echevarria MI, **Strom T**, Abuodeh YA, Ahmed KA, Venkat PS, Trotti A, Harrison LB, Green BL, Yamoah K, Caudell JJ. Treatment delays, race, and outcomes in head and neck cancer. *Cancer Epidemiol*. 2016 Dec;45:18-25. [PMID: 27664388]
12. Mellon EA, **Strom T**, Hoffe SE, Frakes JM, Springett GM, Hodul PJ, Malafa MP, Chuong MD, Shridhar R. Favorable perioperative outcomes after resection of borderline resectable pancreatic cancer treated with neoadjuvant stereotactic radiation and chemotherapy compared with upfront pancreatectomy for resectable cancer. *J Gastrointest Oncol*. 2016 Aug;7(4):547-55. [PMID: 27563444]
13. **Strom T**, Caudell JJ, Harrison LB. Radiotherapy for Management of Basal Cell Carcinoma and Squamous Cell Carcinoma of the Head and Neck. *Cancer Control*. 2016 Jul;23(3):220-7. [PMID: 27556662]
14. Naghavi AO, Echevarria MI, Grass GD, **Strom T**, Abuodeh YA, Ahmed KA, Kim Y, Trotti AM, Harrison LB, Yamoah K, Caudell JJ. Having Medicaid insurance negatively impacts outcomes in patients with head and neck malignancies. *Cancer*. 2016 Aug 1. [PMID: 27479362]
15. **Strom T**, Naghavi AO, Messina JL, Kim S, Torres-Roca JF, Russell J, Sondak VK, Padhya TA, Trotti AM, Caudell JJ, Harrison LB. Improved Local and Regional Control with Radiation Therapy for Merkel Cell Carcinoma of the Head and Neck. *Head Neck*. 2017 Jan;39(1):48-55. [PMID: 27300153]
16. Naghavi AO, **Strom T**, Ahmed KA, Echevarria MI, Abuodeh YA, Venkat PS, Frakes JM, Harrison LB, Trotti AM, Caudell JJ. Management of Oropharyngeal Cancer in the HPV Era. *Cancer Control*. 2016 Jul;23(3):197-207. [PMID: 27556659]
17. **Strom T**, Carr M, Zager JS, Naghavi AO, Smith FO, Cruse CW, Messina JL, Russell J, Rao NG, Fulp W, Torres-Roca JF, Padhya TA, Sondak VK, Harrison LB, Trotti AM, Caudell JJ. Radiation Therapy is Associated with Improved Outcomes in Merkel Cell Carcinoma. *Ann Surg Oncol*. 2016 Oct;23(11):3572-8. [PMID: 27251134]

18. Salem AI, Thau MR, **Strom T**, Abbott AM, Saeed N, Almhanna K, Hoffe SE, Shridhar R, Karl RC, Meredith KL. Effect of body mass index on operative outcome after robotic-assisted Ivor-Lewis esophagectomy: retrospective analysis of 129 cases at a single high-volume tertiary care center. *Dis Esophagus*. 2017 Jan 1;30(1):1-7. [PMID: 27149640]
19. **Strom T**, Wishka C, Caudell JJ. Stereotactic Radiotherapy for Recurrent Unresectable Head and Neck Cancer. *Cancer Control*. 2016 Jan;23(1):6-11. [PMID: 27009451]
20. Frakes JM, Naghavi AO, Demetriou SK, **Strom TJ**, Russell JS, Kish JA, McCaffrey JC, Otto KJ, Padhya TA, Harrison LB, Trotti AM, Caudell JJ. Determining optimal follow-up in the management of human papillomavirus-positive oropharyngeal cancer. *Cancer*. 2016 Feb 15;122(4):634-41. [PMID: 26565997]
21. Hayman TJ, **Strom T**, Springett GM, Balducci L, Hoffe SE, Meredith KL, Hodul P, Malafa M, Shridhar R. Outcomes of resected pancreatic cancer in patients age ≥ 70 . *J Gastrointest Oncol*. 2015 Oct;6(5):498-504. [PMID: 26487943]
22. Frakes JM, **Strom T**, Naghavi AO, Trotti A, Rao NG, McCaffrey JC, Otto KJ, Padhya T, Caudell JJ. Outcomes of mucosal melanoma of the head and neck. *J Med Imaging Radiat Oncol*. 2016 Apr;60(2):268-73. [PMID: 26597431]
23. **Strom T**, Cruz AA, Figura NB, Shrinath K, Nethers K, Mellon EA, Fernandez DC, Saini AS, Hunt DC, Heysek RV, Wilder RB. Health-related quality-of-life changes due to high-dose-rate brachytherapy, low-dose-rate brachytherapy, or intensity-modulated radiation therapy for prostate cancer. *Brachytherapy*. 2015 Nov-Dec;14(6):818-25. [PMID: 26452602]
24. **Strom T**, Harrison LB. Radiotherapy for Management of Basal and Squamous Cell Carcinoma. *Current Problems in Cancer*. 2015 Jul-Aug;39(4):237-47. [PMID: 26364698]
25. **Strom T**, Hoffe SE, Fulp W, Frakes J, Coppola D, Springett GM, Malafa MP, Eschrich SA, Torres-Roca J, Shridhar R. Radiosensitivity Index Predicts for Survival with Adjuvant Radiation in Resectable Pancreatic Cancer. *Radiotherapy and Oncology*. 2015 Oct;117(1):159-64. [PMID: 26235848]
26. Yang G, **Strom T**, Wilder RB, Shrinath K, Mellon EA, Fernandez DC, Biagioli MC. Dosimetric coverage of the prostate, normal tissue sparing, and acute toxicity with high-dose-rate brachytherapy for large prostate volumes. *Int Braz J Urol*. 2015 May-Jun;41(3):435-41. [PMID: 26200536]
27. Frakes JM, Figura NB, Ahmed KA, Juan TH, Patel N, Latifi K, Sarangkasiri S, **Strom T**, Chinnaiyan P, Rao NG, Etame AB. Potential role for LINAC-based stereotactic radiosurgery for the treatment of 5 or more radioresistant melanoma brain metastases. *Journal of Neurosurgery*. 2015 Nov;123(5):1261-7. [PMID: 26140482]
28. **Strom T**, Trotti AM, Kish J, Russell J, Rao NG, McCaffrey J, Padhya TA, Otto KJ, Caudell JJ. Comparison of Every 3 Week Cisplatin or Weekly Cetuximab with Concurrent Radiotherapy for Locally Advanced Head and Neck Cancer. *Oral Oncology*. 2015 Jul;51(7):704-8. [PMID: 25936651]
29. Contreras JA, Wilder RB, Mellon EA, **Strom T**, Fernandez DC, Biagioli MC. Quality of life after high-dose-rate brachytherapy monotherapy for prostate cancer. *Int Braz J Urol*. 2015 Jan-Feb;41(1):40-5. [PMID: 25928509]
30. **Strom T**, Springett GM, Meredith KL, Hoffe SE, Klapman JB, Choi J, Malafa MP, Shridhar R. Comparative Long-Term Outcomes of Upfront Resected Pancreatic Cancer after Preoperative Biliary Drainage. *Surgical Endoscopy*. 2015 Nov;29(11):3273-81. [PMID: 25631110]

31. Mellon EA, Hoffe SE, Springett GM, Frakes JM, **Strom T**, Hodul PJ, Malafa MP, Chuong MD, Shridhar R. Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma. *Acta Oncologica*. 2015 Jul;54(7):979-85. [PMID: 25734581]
32. Frakes JM, **Strom T**, Springett GM, Hoffe SE, Balducci L, Hodul P, Malafa MP, Shridhar R. Resected pancreatic cancer outcomes in the elderly. *Journal of Geriatric Oncology*. 2015 Mar;6(2):127-32. [PMID: 25555451]
33. Mellon EA, Javedan K, **Strom T**, Moros EG, Biagioli MC, Fernandez DC, Wasserman SG, Wilder RB. A dosimetric comparison of volumetric modulated arc therapy with step-and-shoot intensity modulated radiation therapy for prostate cancer. *Practical Radiation Oncology*. 2015 Jan-Feb;5(1):11-5. [PMID: 25413432]
34. Naghavi AO, **Strom T**, Nethers K, Cruz AA, Figura NB, Shrinath K, Yue B, Kim J, Biagioli MC, Fernandez DC, Heysek RV, Wilder RB. Clinical implications of a prostate-specific antigen bounce after radiation therapy for prostate cancer. *International Journal of Clinical Oncology*. 2015 Jun;20(3):598-604. [PMID: 25193155]
35. **Strom T**, Hutchinson SZ, Shrinath K, Cruz AA, Figura NB, Nethers K, Biagioli MC, Fernandez DC, Heysek RV, Wilder RB. External beam radiation therapy and a low-dose-rate brachytherapy boost without or with androgen deprivation therapy for prostate cancer. *International Journal of Brazilian Urology*. 2014 Jul-Aug;40(4):474-83. [PMID: 25251952]
36. **Strom T**, Caudell JJ, Han D, Zager JS, Yu D, Cruse CW, Marzban SS, Messina JL, Trotti AM, Sondak VK, Rao NG. Radiotherapy Influences Local Control in Desmoplastic Melanoma. *Cancer*. 2014 May;120(9):1369-78. [PMID: 24142775]
37. **Strom T**, Wilder RB, Fernandez DC, Mellon EA, Saini AS, Hunt DC, Pow-Sang JM, Spiess PE, Sexton WJ, Poch MA, Biagioli MC. A Dosimetric Study of Polyethylene Glycol Hydrogel in 200 Prostate Cancer Patients Treated with High-Dose Rate Brachytherapy ± Intensity Modulated Radiation Therapy. *Radiotherapy and Oncology*. 2014 Apr;111(1):126-31. [PMID: 24746567]
38. **Strom T**, Wilder RB, Fernandez DC, Mellon EA, Saini AS, Hunt DC and Biagioli MC. High-dose rate brachytherapy with or without intensity modulated radiation therapy as salvage treatment for an isolated, gross local recurrence of prostate cancer post-prostatectomy. *Brachytherapy*. 2014 Mar-Apr;13(2):123-7. [PMID: 24269146]
39. **Strom T**, Trotti AT, Kish J, Rao NG, McCaffrey JC, Padhya TA, Lin H, Fulp W, Caudell JJ. Risk Factors for PEG Tube During Chemoradiotherapy for Oropharynx Cancer. *JAMA Otolaryngology*. 2013 Nov 1;139(11):1242-6. [PMID: 24136493]
40. Reddy K, **Strom T**, Chen C. Primary radiotherapy for locally advanced skin cancer near the eye. *Practical Radiation Oncology*. 2012 Jan;1(2):63-72. [PMID: 24674038]
41. **Strom T**, Kleinschmidt-Demasters BK, Donson A, Foreman NK, Lillehei KO. Rare nerve lesions of non-nerve sheath origin: a 17-year retrospective series. *Archives of Pathology & Laboratory Medicine*. 2009 Sep;133(9):1391-402. [PMID: 19722745]
42. **Strom T**, Shokati T, Klawitter J, Klawitter J, Hoffman K, Schiebel HM, Christians U. Structural identification of SAR-943 metabolites generated by human liver microsomes in vitro using mass spectrometry in combination with analysis of fragmentation patterns. *Journal of Mass Spectrometry*. 2011 Jul;46(7):615-24. [PMID: 21671437]
43. Clavijo C, **Strom T**, Moll V, Betts R, Zhang YL, Christians U, Bendrick-Pearl J. Development and validation of a semi-automated assay for the highly sensitive quantification of Biolimus A9 in human whole blood using high-performance liquid chromatography-tandem mass spectrometry.

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences. 2009 Nov;877(29):3506-14. [PMID: 19762292]

44. Filler G, Bendrick-Peart J, **Strom T**, Zhang YL, Johnson G, Christians U. Characterization of sirolimus metabolites in pediatric solid organ transplant recipients. *Pediatric Transplantation*. 2009 Feb;13(1):44-53. [PMID: 18482220]
45. **Strom T**, Haschke M, Boyd J, Roberts M, Arabshahi L, Marbach P, Christians U. Crossreactivity of isolated everolimus metabolites with the Innofluor Certican immunoassay for therapeutic drug monitoring of everolimus. *Therapeutic Drug Monitoring*. 2007 Dec;29(6):743-9. [PMID: 18043471]
46. **Strom T**, Haschke M, Zhang YL, Bendrick-Peart J, Boyd J, Roberts M, Arabshahi L, Marbach P, Christians U. Identification of everolimus metabolite patterns in trough blood samples of kidney transplant patients. *Therapeutic Drug Monitoring*. 2007 Oct;29(5):592-9. [PMID: 17898649]
47. Boernsen KO, Egge-Jacobsen W, Inverardi B, **Strom T**, Streit F, Schiebel HM, Benet LZ, Christians U. Assessment and validation of the MS/MS fragmentation patterns of the macrolide immunosuppressant everolimus. *Journal of Mass Spectrometry*. 2007 Jun;42(6):793-802. [PMID: 17511017]
48. Christians U, **Strom T**, Zhang YL, Steudel W, Schmitz V, Trump S, Haschke M. Active Drug Transport of Immunosuppressants: New Insights for Pharmacokinetics and Pharmacodynamics. *Therapeutic Drug Monitoring*. 2006 Feb; 28(1):39-44. [PMID: 16418692]
49. Zhang YL, Bendrick-Peart J, **Strom T**, Haschke M, Christians U. Development and Validation of a High-Throughput Assay for Quantification of the Proliferation Inhibitor ABT-578 using LC/LC-MS/MS in Blood and Tissue Samples. *Therapeutic Drug Monitoring*. 2005 Dec; 27(6):770-8. [PMID: 16306853]

Oral Presentations:

1. Radiation Therapy Improves Outcomes with Desmoplastic Melanoma of the Head and Neck. American Radium Society, Kauai, Hawaii. May 3, 2015.
2. A Dosimetric Study of Polyethylene Glycol Hydrogel in 200 Prostate Cancer Patients Treated with High-Dose Rate Brachytherapy ± Intensity Modulated Radiation Therapy. Florida Prostate Cancer Research Symposium, Orlando, FL. Mar 21, 2014.
3. Low-Dose, Involved Field Radiotherapy Just Prior to Radioimmunotherapy for Relapsed/Refractory B-Cell Lymphoma. American Society for Radiation Oncology, Atlanta, GA. Sep 24, 2013.
4. Risk factors for placement of a Percutaneous Endoscopic Gastrostomy tube during chemoradiotherapy for oropharyngeal squamous cell carcinoma. American Head and Neck Society, Orlando, FL. Apr 11, 2013.
5. Rare Nerve Lesions of Non-Nerve Sheath Origin. Western Student Medical Research Forum, Carmel, CA. Jan 30, 2009.
6. Cross-reactivity of the Major Everolimus Hydroxy Metabolites with the Innofluor® Certican Immunoassay for Clinical TDM of Everolimus. International Congress of Therapeutic Drug Monitoring and Clinical Toxicology, Louisville, KY. Apr 25, 2005.

Abstracts/Posters:

List available upon request.